HOME >> BIOLOGY >> NEWS
Monsanto to share technologies with Danforth Center to support global cassava research

ted Nations Human Development Report 2001 also encouraged greater public investment in research and development to ensure that biotechnology is used to meet the agricultural needs of the world's poor.

"By sharing our technology and other scientific knowledge, Monsanto hopes to encourage other companies and technology developers to do the same, said Robb Fraley, Chief Technology Officer of Monsanto.

Working together in public and private sector partnerships promotes a wide variety of discoveries to enhance food security and nutrition throughout the developing world. We look forward to continuing our support of the cassava research program as it develops, said Fraley.

Monsanto also is supporting the Danforth Centers efforts to develop virus-resistant cassava through a multi-year grant from the companys philanthropic organization, the Monsanto Fund. Monsantos contributions to the Danforth Center are in keeping with the New Monsanto Pledge and its commitment to sharing knowledge and technology with public institutions to benefit people and the environment, particularly in the developing world.

In August 2000, Monsanto granted similar royalty-free licenses to the inventors of golden rice, which is being developed to combat vitamin A deficiency in developing countries. Other sharing projects include providing access to a working draft of the rice genome and participating in work to develop virus-resistant sweet potatoes in Africa and papayas in South East Asia.


'"/>

Contact: Shannon Troughton
314-694-2320
Monsanto Company
16-Apr-2002


Page: 1 2

Related biology news :

1. Washington University in St. Louis, Monsanto Co., awarded crop protection patent
2. Monsanto and researchers celebrate first anniversary of sharing rice genome sequence data
3. Monsanto adds support for golden rice; opens its rice genome sequence data to worldwide research community
4. Monsantos modified soya beans dont agree with the heat
5. Bone, enamel, dentine, milk & saliva share gene family
6. K-State researchers share $1 million grant to study insect pests
7. Cross-species comparison reveals shared features between tumorigenesis and organogenesis
8. Scientists discover that metastases share a similar genetic profile to their primary tumour
9. Drug addiction, learning share common brain protein
10. Monkey talk, human speech share left-brain processing
11. Lions share of the best of Asias progressive minds in science and medicine convene

Post Your Comments:
(Date:5/6/2015)... 6, 2015 LifeBEAM, a developer of bio-sensing ... announced today that they will expand their partnership in ... bio-sensing cycling helmet and the first joint project between ... colors in order to give cyclists more style choices ... LifeBEAM and Lazer announced their plan to release a ...
(Date:4/21/2015)... 21, 2015 High crime ... are boosting access control systems market in ... a recently published report by TechSci Research " Saudi ... access control systems market in Saudi Arabia ... 2020.The access control systems market in the Kingdom is ...
(Date:4/14/2015)... Conn. , April 14, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... been nominated for the 2015 New York Design Awards ... The Design100, New York City Design Awards are part ... based on over 2,500 ratings from the marketplace, industry ...
Breaking Biology News(10 mins):LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
(Date:5/22/2015)... 2015 Knowledgent , the data ... explores the potential of big data analytics in the ... developed to help life sciences and healthcare organizations understand ... gain critical business insights. , The life sciences and ... driven by patient profiling, compliance and regulatory requirements, and ...
(Date:5/21/2015)... Specialty Pharmacy Times has completed ... to BPA Worldwide as a business publication member. ... data for Specialty Pharmacy Times based on business/distribution, ... a member of BPA Worldwide, Specialty Pharmacy Times ... with the most reliable, unequaled data,” said Chris ...
(Date:5/21/2015)... May 21, 2015  The EveryLife Foundation for ... (R-UT) and Amy Klobuchar (D-MN) today ... Cures & Treatments, or OPEN ACT. ... advocacy organizations, this bipartisan legislation promises to rapidly ... to rare disease patients by incentivizing drug makers ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
Breaking Biology Technology:New White Paper Explores the Potential of Big Data Analytics in Life Sciences and Healthcare 2Specialty Pharmacy Times Joins BPA Worldwide 2Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7
Cached News: